Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
Claus GarbeUlrike KeimTeresa AmaralCarola BerkingThomas K EigentlerLukas FlatzAnja GesierichUlrike LeiterRudolf StadlerCord SunderkoetterThomas TütingJochen UtikalUwe WollinaLisa ZimmerChristos C ZouboulisPaolo Antonio AsciertoAlexander M M EggermontJean-Jacques GrobAxel HauschildLidija Kandolf SekulovicGeorgina V LongJason John LukeOlivier MichielinKetty PerisDirk SchadendorfJoanne M JeterPaul C Lorigannull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
The melanoma-specific survival rates in the two CMMR cohorts across stages I and II are less favorable than published in AJCCv8. This has important implications for the consideration of adjuvant treatment in this population.